Fulcrum Therapeutics (FULC) Interest Coverage Ratio (QoQ) (2018 - 2026)
Fulcrum Therapeutics (FULC) Interest Coverage Ratio (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121.54% |
| Dec 31, 2025 | 26.78% |
| Sep 30, 2025 | 43.52% |
| Jun 30, 2025 | 60.73% |
| Mar 31, 2025 | -506.35% |
| Dec 31, 2024 | 98.06% |
| Sep 30, 2024 | -555.76% |
| Jun 30, 2024 | 600.43% |
| Mar 31, 2024 | 54.12% |
| Dec 31, 2023 | 13.47% |
| Sep 30, 2023 | 77.95% |
| Jun 30, 2023 | 5.17% |
| Mar 31, 2023 | -5,920.12% |
| Dec 31, 2022 | 98.09% |
| Sep 30, 2022 | 67.96% |
| Jun 30, 2022 | -7,111.58% |
| Mar 31, 2022 | 55.60% |
| Dec 31, 2021 | -216.72% |
| Sep 30, 2021 | 74.46% |
| Jun 30, 2021 | 63.16% |